Toremifene Citrate 60 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 60 mg

Reference Brands: Fareston (USA)

Category: Oncology Cancer Care

Toremifene citrate 60 mg tablets, an oral SERM for oestrogen receptor positive or unknown metastatic breast cancer in postmenopausal women. For importers, distributors and hospital oncology pharmacies.

Product Description:

Toremifene is a selective oestrogen receptor modulator, a chlorinated relative of tamoxifen. In breast tissue it competes with oestrogen for the receptor, so hormone-sensitive cancer cells lose a key growth signal. It comes as a single 60 mg tablet taken once a day. That one fixed strength keeps ordering and dispensing simple and suits long-term outpatient supply, since patients stay on it for as long as it controls their disease.

The licensed use is metastatic breast cancer in postmenopausal women whose tumours are oestrogen receptor positive or of unknown status. The main safety concern is QT prolongation. It is avoided in congenital or acquired long QT, uncorrected low potassium or magnesium and with other QT-prolonging medicines, and strong CYP3A4 inhibitors raise its levels. Patients with bone metastases may develop high calcium in the first weeks. Endometrial thickening can occur, so abnormal vaginal bleeding needs review, and European labelling lists pre-existing endometrial hyperplasia as a contraindication.

Sourcing notes. Toremifene is stocked far less widely than tamoxifen, so check registration in your market and allow for longer lead times. The tablets need no cold chain; store them at room temperature, protected from light. For generic offers, request the bioequivalence summary and the dossier format (CTD or ACTD), with zone IVb stability data for hot, humid regions. Ask for a CoA for each batch, the GMP certificate and a CoPP. It is prescription-only; state pack size, label language and quantity per delivery.